Copyright Reports & Markets. All rights reserved.

Global Myasthenia Gravis Drugs Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Myasthenia Gravis Drugs Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Myasthenia Gravis Drugs Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Myasthenia Gravis Drugs Market Size Growth Rate by Type
    • 1.4.2 Anticholinesterases
    • 1.4.3 Immunosuppressants
    • 1.4.4 Intravenous Immune Globulins
  • 1.5 Market by Application
    • 1.5.1 Global Myasthenia Gravis Drugs Market Size Growth Rate by Application
    • 1.5.2 Hospitals
    • 1.5.3 Clinics
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Myasthenia Gravis Drugs Market Size, Estimates and Forecasts
    • 2.1.1 Global Myasthenia Gravis Drugs Revenue 2015-2026
    • 2.1.2 Global Myasthenia Gravis Drugs Sales 2015-2026
  • 2.2 Global Myasthenia Gravis Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
    • 2.2.1 Global Myasthenia Gravis Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Myasthenia Gravis Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Myasthenia Gravis Drugs Competitor Landscape by Players

  • 3.1 Myasthenia Gravis Drugs Sales by Manufacturers
    • 3.1.1 Myasthenia Gravis Drugs Sales by Manufacturers (2015-2020)
    • 3.1.2 Myasthenia Gravis Drugs Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Myasthenia Gravis Drugs Revenue by Manufacturers
    • 3.2.1 Myasthenia Gravis Drugs Revenue by Manufacturers (2015-2020)
    • 3.2.2 Myasthenia Gravis Drugs Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Myasthenia Gravis Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Myasthenia Gravis Drugs Revenue in 2019
    • 3.2.5 Global Myasthenia Gravis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Myasthenia Gravis Drugs Price by Manufacturers
  • 3.4 Myasthenia Gravis Drugs Manufacturing Base Distribution, Product Types
    • 3.4.1 Myasthenia Gravis Drugs Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Myasthenia Gravis Drugs Product Type
    • 3.4.3 Date of International Manufacturers Enter into Myasthenia Gravis Drugs Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Myasthenia Gravis Drugs Market Size by Type (2015-2020)
    • 4.1.1 Global Myasthenia Gravis Drugs Sales by Type (2015-2020)
    • 4.1.2 Global Myasthenia Gravis Drugs Revenue by Type (2015-2020)
    • 4.1.3 Myasthenia Gravis Drugs Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Myasthenia Gravis Drugs Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Myasthenia Gravis Drugs Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Myasthenia Gravis Drugs Revenue Forecast by Type (2021-2026)
    • 4.2.3 Myasthenia Gravis Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Myasthenia Gravis Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Myasthenia Gravis Drugs Market Size by Application (2015-2020)
    • 5.1.1 Global Myasthenia Gravis Drugs Sales by Application (2015-2020)
    • 5.1.2 Global Myasthenia Gravis Drugs Revenue by Application (2015-2020)
    • 5.1.3 Myasthenia Gravis Drugs Price by Application (2015-2020)
  • 5.2 Myasthenia Gravis Drugs Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Myasthenia Gravis Drugs Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Myasthenia Gravis Drugs Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Myasthenia Gravis Drugs Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Myasthenia Gravis Drugs by Country
    • 6.1.1 North America Myasthenia Gravis Drugs Sales by Country
    • 6.1.2 North America Myasthenia Gravis Drugs Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Myasthenia Gravis Drugs Market Facts & Figures by Type
  • 6.3 North America Myasthenia Gravis Drugs Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Myasthenia Gravis Drugs by Country
    • 7.1.1 Europe Myasthenia Gravis Drugs Sales by Country
    • 7.1.2 Europe Myasthenia Gravis Drugs Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Myasthenia Gravis Drugs Market Facts & Figures by Type
  • 7.3 Europe Myasthenia Gravis Drugs Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Myasthenia Gravis Drugs by Region
    • 8.1.1 Asia Pacific Myasthenia Gravis Drugs Sales by Region
    • 8.1.2 Asia Pacific Myasthenia Gravis Drugs Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Myasthenia Gravis Drugs Market Facts & Figures by Type
  • 8.3 Asia Pacific Myasthenia Gravis Drugs Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Myasthenia Gravis Drugs by Country
    • 9.1.1 Latin America Myasthenia Gravis Drugs Sales by Country
    • 9.1.2 Latin America Myasthenia Gravis Drugs Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Myasthenia Gravis Drugs Market Facts & Figures by Type
  • 9.3 Central & South America Myasthenia Gravis Drugs Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Myasthenia Gravis Drugs by Country
    • 10.1.1 Middle East and Africa Myasthenia Gravis Drugs Sales by Country
    • 10.1.2 Middle East and Africa Myasthenia Gravis Drugs Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Myasthenia Gravis Drugs Market Facts & Figures by Type
  • 10.3 Middle East and Africa Myasthenia Gravis Drugs Market Facts & Figures by Application

11 Company Profiles

  • 11.1 Flamel Technologies
    • 11.1.1 Flamel Technologies Corporation Information
    • 11.1.2 Flamel Technologies Description and Business Overview
    • 11.1.3 Flamel Technologies Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Flamel Technologies Myasthenia Gravis Drugs Products Offered
    • 11.1.5 Flamel Technologies Related Developments
  • 11.2 F. Hoffmann-La Roche
    • 11.2.1 F. Hoffmann-La Roche Corporation Information
    • 11.2.2 F. Hoffmann-La Roche Description and Business Overview
    • 11.2.3 F. Hoffmann-La Roche Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 F. Hoffmann-La Roche Myasthenia Gravis Drugs Products Offered
    • 11.2.5 F. Hoffmann-La Roche Related Developments
  • 11.3 Grifols
    • 11.3.1 Grifols Corporation Information
    • 11.3.2 Grifols Description and Business Overview
    • 11.3.3 Grifols Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Grifols Myasthenia Gravis Drugs Products Offered
    • 11.3.5 Grifols Related Developments
  • 11.4 Pfizer
    • 11.4.1 Pfizer Corporation Information
    • 11.4.2 Pfizer Description and Business Overview
    • 11.4.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 Pfizer Myasthenia Gravis Drugs Products Offered
    • 11.4.5 Pfizer Related Developments
  • 11.5 Takeda
    • 11.5.1 Takeda Corporation Information
    • 11.5.2 Takeda Description and Business Overview
    • 11.5.3 Takeda Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 Takeda Myasthenia Gravis Drugs Products Offered
    • 11.5.5 Takeda Related Developments
  • 11.6 Novartis
    • 11.6.1 Novartis Corporation Information
    • 11.6.2 Novartis Description and Business Overview
    • 11.6.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 Novartis Myasthenia Gravis Drugs Products Offered
    • 11.6.5 Novartis Related Developments
  • 11.7 Bausch Health
    • 11.7.1 Bausch Health Corporation Information
    • 11.7.2 Bausch Health Description and Business Overview
    • 11.7.3 Bausch Health Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 Bausch Health Myasthenia Gravis Drugs Products Offered
    • 11.7.5 Bausch Health Related Developments
  • 11.8 Alexion Pharmaceuticals
    • 11.8.1 Alexion Pharmaceuticals Corporation Information
    • 11.8.2 Alexion Pharmaceuticals Description and Business Overview
    • 11.8.3 Alexion Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 Alexion Pharmaceuticals Myasthenia Gravis Drugs Products Offered
    • 11.8.5 Alexion Pharmaceuticals Related Developments
  • 11.9 Catalyst Pharmaceuticals
    • 11.9.1 Catalyst Pharmaceuticals Corporation Information
    • 11.9.2 Catalyst Pharmaceuticals Description and Business Overview
    • 11.9.3 Catalyst Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Products Offered
    • 11.9.5 Catalyst Pharmaceuticals Related Developments
  • 11.10 CSL
    • 11.10.1 CSL Corporation Information
    • 11.10.2 CSL Description and Business Overview
    • 11.10.3 CSL Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 CSL Myasthenia Gravis Drugs Products Offered
    • 11.10.5 CSL Related Developments
  • 11.1 Flamel Technologies
    • 11.1.1 Flamel Technologies Corporation Information
    • 11.1.2 Flamel Technologies Description and Business Overview
    • 11.1.3 Flamel Technologies Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Flamel Technologies Myasthenia Gravis Drugs Products Offered
    • 11.1.5 Flamel Technologies Related Developments
  • 11.12 Cytokinetics
    • 11.12.1 Cytokinetics Corporation Information
    • 11.12.2 Cytokinetics Description and Business Overview
    • 11.12.3 Cytokinetics Sales, Revenue and Gross Margin (2015-2020)
    • 11.12.4 Cytokinetics Products Offered
    • 11.12.5 Cytokinetics Related Developments
  • 11.13 Galencia
    • 11.13.1 Galencia Corporation Information
    • 11.13.2 Galencia Description and Business Overview
    • 11.13.3 Galencia Sales, Revenue and Gross Margin (2015-2020)
    • 11.13.4 Galencia Products Offered
    • 11.13.5 Galencia Related Developments
  • 11.14 GlaxoSmithKline
    • 11.14.1 GlaxoSmithKline Corporation Information
    • 11.14.2 GlaxoSmithKline Description and Business Overview
    • 11.14.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
    • 11.14.4 GlaxoSmithKline Products Offered
    • 11.14.5 GlaxoSmithKline Related Developments
  • 11.15 Lupin Pharmaceuticals
    • 11.15.1 Lupin Pharmaceuticals Corporation Information
    • 11.15.2 Lupin Pharmaceuticals Description and Business Overview
    • 11.15.3 Lupin Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 11.15.4 Lupin Pharmaceuticals Products Offered
    • 11.15.5 Lupin Pharmaceuticals Related Developments
  • 11.16 Mitsubishi Tanabe Pharma
    • 11.16.1 Mitsubishi Tanabe Pharma Corporation Information
    • 11.16.2 Mitsubishi Tanabe Pharma Description and Business Overview
    • 11.16.3 Mitsubishi Tanabe Pharma Sales, Revenue and Gross Margin (2015-2020)
    • 11.16.4 Mitsubishi Tanabe Pharma Products Offered
    • 11.16.5 Mitsubishi Tanabe Pharma Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Myasthenia Gravis Drugs Market Estimates and Projections by Region
    • 12.1.1 Global Myasthenia Gravis Drugs Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Myasthenia Gravis Drugs Revenue Forecast by Regions 2021-2026
  • 12.2 North America Myasthenia Gravis Drugs Market Size Forecast (2021-2026)
    • 12.2.1 North America: Myasthenia Gravis Drugs Sales Forecast (2021-2026)
    • 12.2.2 North America: Myasthenia Gravis Drugs Revenue Forecast (2021-2026)
    • 12.2.3 North America: Myasthenia Gravis Drugs Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Myasthenia Gravis Drugs Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Myasthenia Gravis Drugs Sales Forecast (2021-2026)
    • 12.3.2 Europe: Myasthenia Gravis Drugs Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Myasthenia Gravis Drugs Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Myasthenia Gravis Drugs Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Myasthenia Gravis Drugs Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Myasthenia Gravis Drugs Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Myasthenia Gravis Drugs Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Myasthenia Gravis Drugs Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Myasthenia Gravis Drugs Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Myasthenia Gravis Drugs Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Myasthenia Gravis Drugs Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Myasthenia Gravis Drugs Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Myasthenia Gravis Drugs Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Myasthenia Gravis Drugs Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Myasthenia Gravis Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter's Five Forces Analysis
  • 13.5 Primary Interviews with Key Myasthenia Gravis Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Myasthenia Gravis Drugs Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Myasthenia Gravis Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Myasthenia Gravis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

    Segment by Type, the Myasthenia Gravis Drugs market is segmented into
    Anticholinesterases
    Immunosuppressants
    Intravenous Immune Globulins

    Segment by Application, the Myasthenia Gravis Drugs market is segmented into
    Hospitals
    Clinics

    Regional and Country-level Analysis
    The Myasthenia Gravis Drugs market is analysed and market size information is provided by regions (countries).
    The key regions covered in the Myasthenia Gravis Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
    Competitive Landscape and Myasthenia Gravis Drugs Market Share Analysis
    Myasthenia Gravis Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Myasthenia Gravis Drugs business, the date to enter into the Myasthenia Gravis Drugs market, Myasthenia Gravis Drugs product introduction, recent developments, etc.

    The major vendors covered:
    Flamel Technologies
    F. Hoffmann-La Roche
    Grifols
    Pfizer
    Takeda
    Novartis
    Bausch Health
    Alexion Pharmaceuticals
    Catalyst Pharmaceuticals
    CSL
    Curavac
    Cytokinetics
    Galencia
    GlaxoSmithKline
    Lupin Pharmaceuticals
    Mitsubishi Tanabe Pharma

    Buy now